Nano Painkiller offers Focus Pain Ablation (FPA) technology as a groundbreaking, non-drug solution for targeted, permanent chronic pain relief.
This innovation addresses the massive global health and economic burden of chronic pain, which affects approximately 20% of the adult Western population and fuels a global drug market valued at $78.41 billion in 2022. The critical need for alternatives stems from the opioid crisis, which has resulted in addiction, overdoses, and deaths, highlighting the failures and risks of current systemic drug therapies.
The core technology uses a molecule comprising Gold Nanoparticles (AuNP), conjugated with a neuronal tracer. This molecule is injected into the painful area and transported retrogradely along the nerve axon to the sensory nerve cell body located in the Dorsal Root Ganglion (DRG). External Ultrasound (US) energy is then applied to the DRG to activate the nanoparticles, causing localized destruction of the specific cell body and silencing the pain signal. This two-stage selectivity ensures that motor nerves are not affected.
The primary business opportunity lies in replacing repeat-intensive procedures and long-term drug dependence with a permanent solution. The initial application targets Knee Osteoarthritis Pain, a condition affecting 300 million people worldwide and valued at $6.76 billion. Compared to current Radiofrequency Ablation (RFA), FPA offers a longer-lasting effect because ablating the DRG cell body prevents nerve regrowth, thereby eliminating the need for repeating treatment every 3–6 months.
